Pancreatic ductal adenocarcinoma (PDAC), which is the primary cause of pancreatic cancer mortality, is poorly responsive to currently available interventions. Identifying new targets that drive PDAC formation and progression is critical for developing alternative therapeutic strategies to treat this lethal malignancy. Using genetic and pharmacological approaches, we investigated in vivo and in vitro whether uptake of the monoamine serotonin [5-hydroxytryptamine (5-HT)] is required for PDAC development. We demonstrated that pancreatic acinar cells have the ability to readily take up 5-HT in a transport-mediated manner. 5-HT uptake promoted activation of the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1), which is required for transdifferentiation of acinar cells into acinar-to-ductal metaplasia (ADM), a key determinant in PDAC development. Consistent with the central role played by Rac1 in ADM formation, inhibition of the 5-HT transporter Sert (Slc6a4) with fluoxetine reduced ADM formation both in vitro and in vivo in a cell-autonomous manner. In addition, fluoxetine treatment profoundly compromised the stromal reaction and affected the proliferation and lipid metabolism of malignant PDAC cells. We propose that Sert is a promising therapeutic target to counteract the early event of ADM, with the potential to stall the initiation and progression of pancreatic carcinogenesis.
Introduction
With an overall 5-year survival rate of <10%, pancreatic ductal adenocarcinoma (PDAC) is a lethal disease [1, 2] . It is estimated that there are >330 000 new cases each year, and PDAC is predicted to become the second leading cause of cancer mortality by 2030, surpassing colorectal, breast and prostate cancer [3] . These statistics clearly underline the need to develop new medical interventions targeting PDAC. Thus, a better understanding of the molecular mechanisms controlling the development of PDAC is imperative to identify and validate alternative therapeutic approaches to counteract this neoplasm.
A molecular hallmark present in 90% of human PDACs is the point mutation (Kras G12D ) in the proto-oncogene KRAS, resulting in the constitutive activation of the protein. Expression of mutant Kras G12D in mouse models is sufficient to recapitulate the early phases of human disease [4] , thus providing a valuable tool with which to identify novel therapeutic targets. In this context, strategies to inhibit Kras expression and activity were considered to be promising for preventing PDAC progression. However, pharmacologicalSerotonin promotes ADM formation 353 An interesting but still rather unexplored Kras effector is Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of the RhoA GTPase family and a master regulator of cytoskeletal dynamics [7] . In recent years, interest in Rac1, in the context of PDAC, increased after the discovery that Rac1-mediated cytoskeletal rearrangements are required to promote the structural changes associated with the development of precursor lesions, namely acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) [8, 9] . As Rac1 deletion improves the survival of Kras G12D mice, pharmacological interventions aimed at inhibiting Rac1 activity have the potential to counteract PDAC onset and progression. In the search for alternative strategies to inhibit Rac1 activity, we focused on post-translational transamidation with the monoamine serotonin [5-hydroxytryptamine (5-HT)]. This process, known as serotonylation, enhances Rac1 activity [10] . Importantly, serotonylation, which relies on intracellular uptake of 5-HT via the 5-HT transporter (Sert, Slc6a4) and on the catalytic activity of transglutaminase-2 (Tgm2), is amenable to pharmacological inhibition [11] . In this context, inhibition of serotonylation by targeting Sert is a particularly attractive option, as selective Sert inhibitors [selective serotonin reuptake inhibitors (SSRIs)] are clinically available.
Previously, our group has demonstrated that 5-HT promotes actin cytoskeleton dynamics in pancreatic acinar cells and ADM formation during the development of pancreatic inflammation [12, 13] . In addition, a very recent publication revealed that 5-HT is locally produced by PDAC cells [14] . As serotonylation enhances Rac1 activity, and Rac1 activation is required for the cytoskeletal reorganization underlining ADM, we investigated whether: (1) 5-HT is necessary for Rac1 activation in pancreatic acinar cells; and (2) pharmacological inhibition of 5-HT uptake with SSRIs prevents the onset of ADM lesions in the setting of PDAC.
Materials and methods
Detailed materials and methods are presented in supplementary material, Supplementary materials and methods.
Biochemical reagents
Stock solutions for fluoxetine (Tocris, Bristol, UK), the Rac1 inhibitor NSC23766 (Tocris) and cerulein (Sigma, Buchs, Switzerland) were made in 0.9% NaCl. Stock solutions for imipramine (Sigma) and cysteamine (Cys) (Sigma) were made in 100% dimethylsulfoxide.
Animal experiments
All animal treatments were performed in accordance with Swiss Federal animal regulations and approved by the cantonal veterinary office of Zurich. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals. Transgenic mice expressing Kras G12D+/flox and mice harboring the Cre transgene under control of the pancreas transcription factor 1α (PTF1α) (PTF1A; PTF1a) promoter (PTF1α cre ; MMRRC, Bar Harbor, ME, USA) were bred to generate PTF1α-cre tg/+ /Kras G12+/flox (Kras G12D ) mice. Mice received 5 mg/kg fluoxetine via drinking water for four consecutive weeks. Pancreatitis was induced in adult (aged 8-10 weeks) wild-type (WT) C57BL/6 (Harlan Laboratories, Horst, The Netherlands) and Tph1 −/− mice on a C57BL/6 background bred in our facility, via six intraperitoneal injections of 50 μg/kg cerulein administered hourly. The harvest times indicated in the figures were calculated from the first cerulein injection. Mice were assigned randomly to different experimental groups for all in vivo studies. Data collection and evaluation of all in vivo and in vitro experiments were performed blind to the group identity.
Mammalian cell culture
The cell lines used in this study were: rat AR42J, human Panc1, mouse Panc02, human BXPC3, rat ARIP, and human umbilical vein endothelial cells (HUVECs). Cells were maintained as described in supplementary material, Supplementary materials and methods.
5-HT uptake in acinar cells
The uptake of [ 3 H]5-HT was measured in AR42J cells and primary pancreatic acini with a protocol designed for rapid uptake determination in cells [15, 16] . Details are provided in supplementary material, Supplementary materials and methods.
Three-dimensional (3D) in vitro ADM formation
Primary acinar cell cultures were prepared according to [17] and as detailed in supplementary material, Supplementary materials and methods. Cultures were incubated with 20 μM fluoxetine, 20 μM imipramine, 100 μM Rac1 inhibitor NSC23766 (iRac1), 1 mM Cys, and 10 μM SB204741 [a selective antagonist of 5-HT receptor 2B (5-HT 2B )]. All compounds were applied daily on collagen-embedded acini following the preventive or therapeutic regimens shown in Figure 3G .
Spheroid formation
One thousand BXPC3 cells were seeded in RPMI medium with 10% fetal bovine serum and allowed to form spheroids in ultralow attachment 96-well plates (COSTAR; Sigma). Cells were treated with 20 μM fluoxetine 1 h after seeding, and incubated with the drug for 72 h. ATP measurements were performed with a Cell Titer-Glo Luminescent Cell Viability Assay (Promega, Duebendorf, Switzerland).
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Rac1 activation assay
A Rac1 G-LISA Activation Assay Kit (Cytoskeleton, Denver, CO, USA) was utilized to determine Rac1 activation in frozen pancreatic tissues, according to the manufacturer's protocol.
Fluorescence resonance energy transfer (FRET)
FRET assays of AR42J cells transduced with lentiviruses encoding for Rac1 second-generation (Rac1-2G) biosensor [19] were performed according to a previously described protocol [20] , and as detailed in supplementary material, Supplementary materials and methods.
Chorioallantoic membrane (CAM) assay
The CAM assay, using fertilized Lowman white LSL chick eggs (Animalco AG Gefleügelzucht, Staufen, Switzerland), was performed as described previously [21] , and as detailed in supplementary material, Supplementary materials and methods.
Immunohistochemistry
Pancreas specimens were fixed and embedded in paraffin for histological analyses as described previously [22] . For immunofluorescence analysis of cultured cell lines, cells were fixed in 3.6% formaldehyde and permeabilized with 0.2% Triton X-100 in phosphate-buffered saline. The primary antibodies used in this study are listed in supplementary material, Supplementary materials and methods.
Transcriptome analysis
Pancreas specimens and collagen-embedded cells were processed as described previously [23, 24] . Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany), 1 μg of RNA was reverse-transcribed by the use of qScript cDNA SuperMix (QuantaBio, Beverly, CA, USA), and 2.4 μl of cDNA was used for reverse transcription quantitative polymerase chain reaction (RT-qPCR). Taqman probes (Applied Biosystems, Foster City, CA, USA) were used for the RT-qPCR reaction.
RNA-sequencing (RNA-seq) analysis
Human Panc1 cells were seeded in six-well plates at the density of 5 × 10 5 cells per well, and treated with 20 μM fluoxetine or solvent for 24 or 72 h. A detailed description of library preparation, cluster generation and sequencing, data analysis and gene set enrichment analysis (GSEA) is given in supplementary material, Supplementary materials and methods. Array-based technology: raw data are supplied as supplementary material, Table S1 .
Statistical analyses
Groups of five or six mice were used for each experiment. Data are expressed as mean ± standard error of the mean (SEM). The statistical significance of differences in the means of experimental groups was determined with an unpaired, two-tailed Student's t-test, unless otherwise stated; p < 0.05 was considered to be significant.
Results
Intracellular 5-HT is required for Rac1 activation in pancreatic acinar cells 5-HT promotes the activity of small GTPases by covalently binding to highly conserved glutamine residues, a process called serotonylation [11, 25] . Increased activation of serotonylated Rac1 was linked to reduced hydrolysis of bound GTP via a mechanism not yet identified [11] . To investigate this activation mechanism, we performed in silico modeling of the human Rac1 crystal structure in complex with 5-HT at the previously identified serotonylation site at position 61 [11] . Notably, this residue is also susceptible to a leucine substitution that results in constitutive activation of this protein [26] . The modeling indicated that the location of the hydrophobic part of 5-HT, similarly to the hydrophobic side chain of leucine, would transiently inhibit the interaction between bound GTP and surrounding water molecules ( Figure 1A ), thus reducing the likelihood of GTP hydrolysis and prolonging Rac1 activity.
We then assessed whether lack of 5-HT reduces the levels of Rac1 activation in pancreatic acinar cells in vivo. Acinar activation of Rac1 is stimulated in mice upon treatment with the cholecystokinin analog cerulein [27] . Cerulein-induced Rac1 activation was not observed in pancreatic tissue deficient in 5-HT from mice lacking the 5-HT synthetic enzyme tryptophan hydroxylase 1 (Tph1) [28] (Figure 1B ), thus confirming that 5-HT availability is required for cerulein-induced Rac1 activation in pancreatic cells. Furthermore, we found that uptake of [ 3 H]5-HT in both freshly isolated pancreatic acinar cells and in the acinar cell line AR42J was transporter-mediated and inhibited by the Sert inhibitor fluoxetine ( Figure 1C ), resulting in a reduced amount of proteins modified by serotonylation ( Figure 1D ). Notably, AR42J cells expressed transcripts for the enzyme Tph1 (supplementary material, Figure S1B ), suggesting endogenous production of 5-HT. Importantly, inhibition of 5-HT uptake with fluoxetine in AR42J acinar cells abrogated cerulein-induced Rac1 activation, as demonstrated by FRET imaging. For this analysis, AR42J acinar cells were transduced with lentiviruses encoding a Rac1-2G biosensor [19] , as shown in Figure 1E . Under these conditions, yellow fluorescent protein (YFP)-labeled Rac1 binds to its cyan fluorescent protein (CFP)-labeled Pak effector domain only in its GTP-bound state. Fluoxetine treatment of cerulein-stimulated AR42J cells reduced Rac1 activa kinase 1 (Pak1) [31] in AR42J cells ( Figure 1G ). Collectively, these data indicate that pharmacological inhibition of 5-HT uptake with fluoxetine abrogates activation of Rac1 in pancreatic acinar cells.
Fluoxetine treatment reduces Kras-induced ADM formation in vitro
As Rac1 activation is a prerequisite for cytoskeletal rearrangements leading to ADM formation [8] , and inhibition of 5-HT uptake with fluoxetine abrogated Rac1 activation ( Figure 1F ), we tested whether fluoxetine treatment prevents ADM formation. To this end, we utilized a 3D culture system in which acinar explants were isolated from P48 +/-Cre ;LSL-Kras G12D (Kras G12D ) mice, which are prone to developing PDAC precursor lesions [32] . Kras G12D acinar explants spontaneously transdifferentiate into ADM in the absence of inflammatory and stromal cells [17] . A few days after embedding in collagen, Kras G12D acini underwent a considerable structural change (Figure 2A ), accompanied by reduced expression of terminal differentiated genes, such as the amylase gene (Amy1a) and Mist1 ( Figure 2B ), and upregulation of ADM markers, namely Ck19, Sox9 and the β-catenin gene (Ctnnb1) (Figure 2C ), and Rac1 signaling components (Tiam1 and Pak1) ( Figure 2D ). Importantly, ADM formation in vitro was characterized by upregulation of genes involved in 5-HT signaling and metabolism: Tgm2, the 5-HT 2B gene (Htr2b), and Maoa ( Figure 2E ). Unexpectedly, Sert (Slc6a4) expression was downregulated during ADM formation ( Figure 2E ; supplementary material, Figure S2A ), whereas levels of the 5-HT synthetic enzyme Tph1 were elevated in all Kras samples as compared with WT acini ( Figure 2F ).
We then evaluated whether fluoxetine treatment compromised ADM formation by applying the drug in a preventive manner, concomitant with acinar cell embedding, or in a therapeutic manner, after acinar transdifferentiation, according to the scheme depicted in Figure 2G . Preventive fluoxetine treatment completely prevented ADM formation ( Figure 2H,I ) and actin cytoskeleton remodeling ( Figure 2J) . Notably, reduction of ADM formation was achieved upon inhibition of the serotonylating enzyme Tgm2 with Cys, and of Rac1 activity with iRac1 ( Figure 2I ), confirming that serotonylation and Rac1 activity are two critical factors promoting acinar cell transdifferentiation. Therapeutic fluoxetine treatment was also effective in perturbing already formed ADM, and resulted in destabilization and a reduction in size of transdifferentiated structures ( Figure 2K ). Similar inhibition of ADM formation was observed when the structurally different Sert inhibitor imipramine was used in a preventive and therapeutic manner (supplementary material, Figure S2B ), further demonstrating that SSRI treatment interferes with acinar cell transdifferentiation. Collectively, our data reveal that fluoxetine treatment inhibits Kras-induced ADM formation in vitro in a cell-autonomous manner.
Next, we tested whether 5-HT signaling mediated by 5-HT 2B promoted ADM formation. We focused on this receptor because its expression increases during ADM formation and its function is crucial to support PDAC growth [14] . Interestingly, we found that 5-HT 2B inhibition with SB204741 did not reduce the number of acinar cells undergoing ADM or affect ADM morphology ( Figure 2L ), suggesting that the receptor signaling is dispensable for the early steps of acinar transdifferentiation.
Fluoxetine treatment reduces Kras-induced ADM formation in vivo
We then tested whether fluoxetine reduced ADM formation in vivo. Kras G12D mice showed the first ADM at 5 weeks of age; this then progressed to widespread lesions at 10 weeks of age ( Figure 3A) . At both of these time points, Kras G12D pancreata showed upregulation of genes involved in Rac1 signaling (Tiam1 and Pak1) ( Figure 3B ) and conspicuous Rac1 localization on plasma membranes in ADM lesions ( Figure 3C ), supporting the finding of increased Rac1 activation during ADM formation reported previously [9] . Kras G12D pancreata also showed regulation of genes involved in 5-HT signaling and metabolism ( Figure 3D ). Specifically, as observed during ADM formation in vitro, the levels of mRNAs encoding enzymes involved in serotonylation (Tgm2), 5-HT synthesis (Tph1) and extracellular 5-HT signaling [5-HT 2B (Htr2b)] were upregulated, whereas the levels of mRNAs encoding the 5-HT transporter (Sert) decreased over time.
In this context, we also found that genes of the 5-HT signaling system were deregulated when we compared their expression in isolated pancreatic acini with that in Panc02 PDAC cells, including pronounced upregulation of the 5-HT synthetic enzyme gene Tph1 (supplementary material, Figure S3A ). Levels of Tgm2 and Sert mRNAs decreased in Panc02 cells, but their RNAs were still detectable (supplementary material, Figure S3B ). Decreased levels of SERT RNA were found in a meta-analysis of four human datasets (GSE15471, GSE16515, GSE22780, and hGSE32688) (supplementary material, Figure S3C ), but not in the RNA-seq data reported in [33] (supplementary material, Figure S3D ). Importantly, analysis of protein expression revealed that TPH1, TGM2 (supplementary material, Figure S3E , from http://www.proteinatlas.org/) and SERT [14] were present in human PDAC samples.
Five weeks of fluoxetine administration in young mice (5 weeks of age) significantly reduced the size of precursor lesions in the pancreas, as quantified by histological evaluation and mucin staining ( Figure 3E) , and decreased the expression of the Rac1 effector Pak1 (supplementary material, Figure S4) . A detailed histopathological analysis revealed that fluoxetine reduced the occurrence of ADM, atypical flat lesions (AFLs), and cancerous initiating foci (Table 1) .
Continuous Kras signaling in the pancreas induces a stromal profibrotic and proinflammatory microenvironment that promotes neoplastic progression [34] [35] [36] . Notably, both fibrosis and inflammatory cell infiltration were hampered upon fluoxetine treatment. This was apparent from reduced levels of α-smooth muscle actin (α-SMA), which is expressed during pancreatic stellate cell (PSC) activation, and reduced deposition of collagen, produced by activated PSCs ( Figure 3F) . Similarly, the levels of F4/80-positive macrophages and CD3-positive T-lymphocytes infiltrating the pancreas were reduced in fluoxetine-treated mice ( Figure 3G ). Concomitantly, gene expression of tumor necrosis factor-α (Tnfα, Tnf ), monocyte chemoattractant protein 1 (Mcp1, Ccl2) and interleukin-6 (Il-6, Il6), which are proinflammatory mediators of PDAC progression [37, 38] , decreased upon fluoxetine treatment (supplementary material, Figure S5 ). Finally, fluoxetine-treated Kras G12D mice showed a reduced number of blood vessels in pancreatic lesions ( Figure 3H ).
Taken together, these results indicate that fluoxetine treatment of Kras G12D mice is associated with reduced lesion formation and attenuated stromal reaction.
Fluoxetine counteracts tumor growth and its associated angiogenesis
On the basis of the reduced vascularization observed in the lesions of fluoxetine-treated Kras G12D mice ( Figure 3H ), we further investigated whether fluoxetine directly impacts on endothelial cells and vessel formation. In support of this hypothesis, fluoxetine destabilized angiogenesis in vitro, as assessed by matrigel-based tube formation of HUVECs ( Figure 4A ), and reduced HUVEC proliferation ( Figure 4B ; supplementary material, Figure S6 ). Notably, these cells did not express SERT (supplementary material, Figure S6B , and [39] ), and their 5-HT uptake is mediated by additional transporters, including plasma membrane monoamine transporter (PMAT) [39] , which is expressed in our cell culture (supplementary material, Figure S6C ). Importantly, PMAT-mediated 5-HT transport is also inhibited by fluoxetine [40, 41] . HUVECs expressed TPH1 transcripts (Figure S6D ), suggestive of endogenous 5-HT production. Furthermore, fluoxetine treatment impaired vascularization of CAMs, as shown by by reduced vessel density ( Figure 4C ) and diameter ( Figure 4D ).
We then examined whether fluoxetine inhibits angiogenesis in the context of PDAC tumor growth. To this end, we exploited a recently described ex vivo tumor model that histologically and proteomically mimics human PDAC, consisting of human PDAC cells (BXPC3) engrafted on CAMs [21] . Similarly to what was observed in HUVECs, BXPC3 cells expressed TPH1 transcripts (supplementary material, Figure S6E ), suggesting endogenous production of 5-HT. Upon fluoxetine treatment, BXCP3 cells did not grow into a visible tumor mass ( Figure 4E ), showed a reduced extent of vascularization ( Figure 4E, arrowheads) , and did not form organized CK19-positive clusters in the matrix ( Figure 4F ). The lack of BXPC3 cluster formation was not the result of inhibited cell-to-cell aggregation, because BXPC3 cells were able to generate anchorage-independent 3D spheroids in suspension upon fluoxetine treatment ( Figure 4G ). However, in the presence of the drug, BXPC3 spheroids showed poorly defined edges ( Figure 4G, arrow) , darker cores ( Figure  4G , arrowhead), abundant cellular debris ( Figure  4G, asterisks) , and earlier decreases in ATP levels ( Figure 4H ). It is noteworthy that 3D spheroids represent the most versatile method with which to evaluate drug efficacy, as they closely resemble native tumors, and are typically more resistant to chemotherapeutics and radiotherapeutics than their two-dimensional (2D) counterparts [42, 43] . Collectively, our data indicate that fluoxetine treatment causes synergistic inhibition of angiogenesis and tumor growth. reduced angiogenesis and from direct inhibition of cell proliferation by the drug. To test the latter, we quantified the time course of proliferation of a panel of PDAC cells of human, mouse and rat origin in the presence of fluoxetine. In particular, human PDAC cells were characterized by different adhesion ability, tumorigenesis, and genotype, with KRAS being mutated in Panc1 cells but not in BXPC3 cells (reviewed in [44] ). Fluoxetine inhibited proliferation of all PDAC cells tested ( Figure 5A ), suggesting an antitumorigenic effect conserved among species. Similar inhibition of Panc1 cell proliferation was observed upon treatment with iRac1 (supplementary material, Figure S7 ).
We then tested the global effects of time-course362 E Saponara et al expression of genes involved in cell cycle progression and cell division ( Figure 5B ). In addition, we found that fluoxetine robustly upregulated genes involved in lipid metabolism. This unexpected alteration of cellular metabolism was further confirmed by abundant intracellular accumulation of free cholesterol, as demonstrated by filipin staining ( Figure 5C ) and quantitative thin-layer chromatography ( Figure 5C ). In conclusion, our data demonstrate that fluoxetine treatment inhibits cell proliferation and alters lipid metabolism of human PDAC cells.
Discussion
The formation of precursor lesions in the pancreas is a critical event in the progression to malignant PDAC. Among the precursor lesions identified so far, ADMs not only constitute the initial stage of the metaplastic transformation, but are also now considered to be at the core of an alternative model of pancreatic tumorigenesis whereby PDAC can directly originate from the acinar-centroacinar compartment via the formation of AFLs (reviewed in [45] ).
In this study, we have demonstrated that intracellular availability of 5-HT is required for ADM formation and maintenance in vitro and in vivo. In addition, we showed that 5-HT uptake is a pharmacological target to counteract the development of PDAC. Specifically, we discovered that 5-HT is required in pancreatic acinar cells for intracellular activation of Rac1, a crucial regulator of actin cytoskeleton remodeling (recently reviewed in [46, 47] ). This protein is of special interest in the context of PDAC development, as Rac1 is upregulated in murine and human pancreatic samples [8, 9] as a consequence of an activating mutation of Kras. In addition, despite many downstream effectors activated by Kras, Rac1 ablation is sufficient to reduce Kras-induced pancreatic tumorigenesis [8] . Using genetic and pharmacological models, we now demonstrate that Rac1 activation depends on the availability of intracellular 5-HT, probably via transglutaminase-dependent serotonylation (reviewed in [48] ).
Another feature that emerged from our analyses is that the expression of genes involved in 5-HT synthesis and signaling increased with the level of cell malignancy. A similar regulation pattern was observed at the protein level in human PDAC specimens (http://www .proteinatlas.org/) and in a recent report [14] . Collectively, these findings support the interesting hypothesis that increased endogenous synthesis of 5-HT would provide pancreatic cancer cells with increased autonomy of 5-HT production, and consequently would reduce their dependency on 5-HT delivered by circulating platelets. 5-HT production could result in activation of the two major pathways required for 5-HT signaling, namely: (1) 5-HT uptake, which is necessary for serotonylation of intracellular proteins; and (2) activation of 5-HT receptors, and consequent signal transduction. In this context, a very recent study demonstrated that 5-HT signaling via 5-HT 2B is required for PDAC cell growth [14] . Our data, showing that the initial transdifferentiation of acinar cells into ADM is blocked by inhibiting 5-HT uptake but not 5-HT 2B , raises the intriguing hypothesis that 5-HT uptake is an initial requirement for the formation of precursor lesions, which precedes the involvement of 5-HT signaling via 5-HT 2B .
In the context of gene regulation of cellular components involved in 5-HT signaling, it is interesting to note the apparent time-dependent reduction in Sert expression during tumorigenesis, although the protein was abundant in both human and murine PDAC specimens [14] . The precise mechanisms regulating Sert expression are yet to be fully elucidated; however, it is possible that increased 5-HT synthesis during tumor formation induces Sert downregulation, as previously reported in an in vitro system [49] .
Another important observation derived from our work is that fluoxetine not only inhibited the formation of premalignant lesions, but also reduced the proliferation of malignant PDAC cells, restrained their growth in a CAM-based tumor model, and altered their lipid metabolism. The lipid alteration observed upon inhibition of 5-HT uptake complements previous finding showing that inhibition of 5-HT 2B signaling reduces the glycolysis required for PDAC growth [14] , thus underlining the central role played by 5-HT in the metabolism of PDAC cells. In addition, our in vivo and in vitro results highlighted the fact that fluoxetine reduced the stromal reaction that surrounds pancreatic lesions, as shown by decreased fibrosis, inflammation, and angiogenesis. These promising data have important clinical implications, as fluoxetine treatment may be beneficial not only in the early phases of metaplastic lesions but also during full-blown tumorigenesis and metastatic spreading. In this context, given that different cell types may express different 5-HT transporters, including PMAT and organic cation transporter 1, and that fluoxetine targets these transporters in addition to Sert [41, 50] , future investigations are needed to elucidate the identity of the transporters involved in the observed phenotypes.
Collectively, our results set the foundation for further investigation of the molecular factors targeted by the drug in PDAC and stromal cells, as it is plausible that fluoxetine modulates cellular functions of different cell types via multiple mechanisms.
For instance, fluoxetine may inhibit PDAC proliferation by preventing Rac1 activation. In support of this hypothesis, we observed similar inhibition of Panc1 proliferation upon treatment with fluoxetine or the Rac1 inhibitor NSC23766, and that Rac1 activation is critical for promoting growth of PDAC cells [51] .
Similarly, the broad range of signaling pathways activated by Rac1 could also explain the metabolic alterations and increased lipogenesis observed in Panc1 cells upon fluoxetine treatment. In this regard, Rac1 activation was reported to regulate cholesterol metabolism in macrophages [52] . In an alternative mechanism, fluoxetine was also reported to increase lipid accumulation Serotonin promotes ADM formation 363 in hepatocytes by promoting SREBP1c-related lipogenesis and suppressing the AMP-activated protein kinase signaling pathway [53, 54] . However, given that other small GTPases can be activated by serotonylation, it is possible that Rac1-independent mechanisms contribute to the observed phenotypes.
In conclusion, our data reveal that intracellular uptake of 5-HT is required for Rac1 activation, which is the basis of acinar cell transdifferentiation into premalignant ADM lesions. In addition, we showed that fluoxetine counteracts not only the formation of premalignant lesions but also the growth of malignant PDAC cells, probably via the concerted inhibitory effects on cancer and stromal cells. In this context, further research is warranted to promote clinical translation of these results. Specifically, future investigations of the efficacy of fluoxetine on the recently identified PDAC subtypes with diverse therapy responses [55] , and as combination therapy with currently used anti-PDAC interventions, are of special interest. 
